Approved regulatory verdict
Evidence outlook
Approved: Non-Small Cell Lung Cancer (label: metastatic NSCLC with a BRAF V600E mutation, with binimetinib)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Non-Small Cell Lung Cancer · approved · Featured evidence · 3 approved Featured evidence · 3
Competitive landscape 61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Encorafenib: this drug Approved Small molecule BRAF V600E HLX208 Phase 2 Small molecule BRAF V600E Afatinib (Gilotrif)Approved Small molecule EGFR/HER1, HER2, HER4 Alectinib (Alecensa)Approved Small molecule ALK Alymsys (bevacizumab-Maly) Approved Monoclonal antibody VEGF-A Amivantamab Approved Multispecific antibody EGFR x c-MET Atezolizumab Approved Monoclonal antibody PD-L1 BAT1706 (Avzivi)Approved Monoclonal antibody VEGF-A BAY2927088 (Hyrnuo)Approved Small molecule HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR Bevacizumab Approved Monoclonal antibody VEGF-A , Vascular Endothelial Growth Factor Inhibitor Bevacizumab-Awwb (MVASI)Approved Monoclonal antibody VEGF-A Binimetinib Approved Small molecule MEK1/2 Brigatinib Approved Small molecule ALK Capmatinib Approved Small molecule MET Cemiplimab Approved Monoclonal antibody PD-1 Ceritinib Approved Small molecule ALK
…and 46 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (24 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4) October 2026 (1) Phase 3 Melanoma Active not recruiting
Est. primary completion 2026-10-30 ·
NCT04657991 ·
CT.gov ↗ What to watch December 2026 (3) Phase 2 Solid Tumor Active not recruiting
Est. primary completion 2026-12 ·
NCT03839342 ·
CT.gov ↗ What to watch Phase 3 Metastatic Colon Cancer, Stage III Colon Cancer Active not recruiting
Est. primary completion 2026-12 ·
NCT03803553 ·
CT.gov ↗ What to watch Phase 2 Colorectal Cancer, BRAF V600E Mutation Positive Recruiting
Est. primary completion 2026-12-30 ·
NCT05706779 ·
CT.gov ↗ What to watch 2027 (11) January 2027 (1) Phase 1 Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma … Recruiting
Est. primary completion 2027-01-30 ·
NCT06102902 ·
CT.gov ↗ What to watch February 2027 (1) Phase 2 Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8 Recruiting
Est. primary completion 2027-02-02 ·
NCT05026983 ·
CT.gov ↗ What to watch March 2027 (1) Phase 3 Melanoma Active not recruiting
Est. primary completion 2027-03-31 ·
NCT05270044 ·
CT.gov ↗ What to watch April 2027 (1) Phase 1 Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation Recruiting
Est. primary completion 2027-04 ·
NCT04741997 ·
CT.gov ↗ What to watch May 2027 (1) Phase 2 Metastatic Colorectal Cancer Recruiting
Est. primary completion 2027-05-01 ·
NCT06411600 ·
CT.gov ↗ What to watch June 2027 (2) Phase 3 Biliary Tract Neoplasms Recruiting
Est. primary completion 2027-06 ·
NCT05615818 ·
CT.gov ↗ What to watch Phase 2 Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma … Recruiting
Est. primary completion 2027-06-30 ·
NCT04511013 ·
CT.gov ↗ What to watch November 2027 (1) Phase 1 Dynamic Tumor Resistance, Metastatic Colorectal Cancer Not yet recruiting
Est. primary completion 2027-11-14 ·
NCT07318389 ·
CT.gov ↗ What to watch December 2027 (3) Phase 2 Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 … Active not recruiting
Est. primary completion 2027-12-08 ·
NCT02910700 ·
CT.gov ↗ What to watch Phase 1/2 BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma … Active not recruiting
Est. primary completion 2027-12-30 ·
NCT04017650 ·
CT.gov ↗ What to watch Phase 2 BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma … Active not recruiting
Est. primary completion 2027-12-30 ·
NCT04061980 ·
CT.gov ↗ What to watch 2028 (5) January 2028 (2) Phase 2 Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases Recruiting
Est. primary completion 2028-01 ·
NCT06887088 ·
CT.gov ↗ What to watch Phase 1/2 Cutaneous Melanoma, Brain Metastases Recruiting
Est. primary completion 2028-01-15 ·
NCT06194929 ·
CT.gov ↗ What to watch February 2028 (1) Phase 2 Colo-rectal Cancer Not yet recruiting
Est. primary completion 2028-02 ·
NCT07178717 ·
CT.gov ↗ What to watch March 2028 (1) Phase 1 Metastatic Colorectal Cancer Recruiting
Est. primary completion 2028-03-28 ·
NCT05985954 ·
CT.gov ↗ What to watch July 2028 (1) Phase 1 Metastatic Melanoma, BRAF Gene Mutation Recruiting
Est. primary completion 2028-07-01 ·
NCT04903119 ·
CT.gov ↗ What to watch 2029 (2) April 2029 (1) Phase 2 Colorectal Cancer Recruiting
Est. primary completion 2029-04-01 ·
NCT06207656 ·
CT.gov ↗ What to watch July 2029 (1) Phase 4 Solid Tumors Recruiting
Est. primary completion 2029-07-31 ·
NCT05203172 ·
CT.gov ↗ What to watch 2034 (1) June 2034 (1) Phase 2/3 Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8 … Active not recruiting
Est. primary completion 2034-06-01 ·
NCT05710406 ·
CT.gov ↗ What to watch 2038 (1) December 2038 (1) Phase 2 Metastatic Colorectal Cancer Recruiting
Est. primary completion 2038-12-31 ·
NCT05725200 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (84) Non-Small Cell Lung Cancer (7) Other / comorbidity (77)
Phase 3 (7) Phase 2/3 (1) Phase 2 (45) Phase 1/2 (11) Phase 1 (17) Phase 4 (2) Early phase / not applicable (1)